Systematic review: Persistent reflux symptoms on proton pump inhibitor therapy in primary care and community studies

Alimentary Pharmacology and Therapeutics

Volumn 32, Issue 6, 2010, Pages 720-737

  El Serag, H ^a   Becher, A ^b   Jones, R ^c  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

^b OXFORD PHARMAGENESIS LTD   (United Kingdom)

^c KING'S COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CISAPRIDE; ESOMEPRAZOLE; LANSOPRAZOLE; OMEPRAZOLE; RABEPRAZOLE; RANITIDINE;

ANXIETY; COMBINATION CHEMOTHERAPY; CONFIDENCE INTERVAL; DEPRESSION; DISEASE SEVERITY; DYSPEPSIA; EMBASE; EPIGASTRIC BURNING; EPIGASTRIC PAIN; EUROPE; FEAR; FOOD REGURGITATION; GASTROESOPHAGEAL REFLUX; GASTROINTESTINAL ENDOSCOPY; GENDER; HEARTBURN; HELICOBACTER INFECTION; HIATUS HERNIA; HUMAN; INDIGESTION; MEDLINE; NAUSEA; OBSERVATIONAL STUDY; ODYNOPHAGIA; PAIN; PHYSICAL PERFORMANCE; PREVALENCE; PRIMARY MEDICAL CARE; PRIORITY JOURNAL; PSYCHOLOGICAL WELL BEING; REFLUX ESOPHAGITIS; REVIEW; RISK ASSESSMENT; SAMPLE SIZE; SLEEP DISORDER; SOMATIZATION; SYSTEMATIC REVIEW; TREATMENT DURATION; TREATMENT RESPONSE; UNITED STATES;

CLINICAL TRIALS AS TOPIC; COMMUNITY HEALTH SERVICES; GASTROESOPHAGEAL REFLUX; GASTROINTESTINAL AGENTS; HUMANS; PRIMARY HEALTH CARE; PROTON PUMP INHIBITORS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; TREATMENT OUTCOME;

EID: 77955740923     PISSN: 02692813     EISSN: 13652036     Source Type: Journal    
DOI: 10.1111/j.1365-2036.2010.04406.x     Document Type: Review

References (46)

1. Vakil N, Veldhuyzen van Zanten S, Kahrilas P, Dent J, Jones R. The Montreal definition and classification of gastro-esophageal reflux disease (GERD) - a global evidence-based consensus. Am J Gastroenterol 2006 101 : 1900 1920.
2. Bredenoord AJ, Weusten BL, Curvers WL, Timmer R, Smout AJ. Determinants of perception of heartburn and regurgitation. Gut 2006 55 : 313 318.
3. Dent J, El-Serag HB, Wallander MA, Johansson S. Epidemiology of gastro-oesophageal reflux disease: a systematic review. Gut 2005 54 : 710 717.
4. Wong BCY, Kinoshita Y. Systematic review on epidemiology of gastroesophageal reflux disease in Asia. Clin Gastroenterol Hepatol 2006 4 : 398 407.
5. Dent J. Microscopic esophageal mucosal injury in nonerosive reflux disease. Clin Gastroenterol Hepatol 2007 5 : 4 16.
6. Dent J. Review article: from 1906 to 2006 - a century of major evolution of understanding of gastro-oesophageal reflux disease. Aliment Pharmacol Ther 2006 24 : 1269 1281.
7. van Pinxteren B, Numans ME, Bonis PA, Lau J. Short-term treatment with proton pump inhibitors, H2-receptor antagonists and prokinetics for gastro-oesophageal reflux disease-like symptoms and endoscopy negative reflux disease. Cochrane Database Syst Rev 2004 18 : CD002095.
8. Donnellan C, Sharma N, Preston C, Moayyedi P. Medical treatments for the maintenance therapy of reflux oesophagitis and endoscopic negative reflux disease. Cochrane Database Syst Rev 2005 4 : CD003245.
9. Bland JM, Kerry SM. Statistics notes. Weighted comparison of means. BMJ 1998 316 : 129.
10. Edwards SJ, Lind T, Lundell L, Das R. Systematic review: standard- and double-dose proton pump inhibitors for the healing of severe erosive oesophagitis - a mixed treatment comparison of randomized controlled trials. Aliment Pharmacol Ther 2009 30 : 547 556.
11. Jian R, Hassani Z, El Kebir S, Barthelemy P. Management of gastro-esophageal reflux disease in primary care. Results from an observational study of 2,474 patients (AO). Gastroenterol Clin Biol 2007 31 : 72 7.
12. Jones R, Liker HR, Ducrotté P. Relationship between symptoms, subjective well-being and medication use in gastro-oesophageal reflux disease. Int J Clin Pract 2007 61 : 1301 1307.
13. Bretagne JF, Honnorat C, Richard-Molard B, Caekaert A, Barthelemy P. Comparative study of characteristics and disease management between subjects with frequent and occasional gastro-oesophageal reflux symptoms. Aliment Pharmacol Ther 2006 23 : 607 616.
14. Robinson M, Shaw K. Proton pump inhibitor attitudes and usage: a patient survey. Pharm Ther J 2002 27 : 202 206.
15. van der Velden AW, de Wit NJ, Quartero AO, Grobbee DE, Numans ME. Maintenance treatment for GERD: residual symptoms are associated with psychological distress. Digestion 2008 77 : 207 213.
16. Brun J, Sorngard H. High dose proton pump inhibitor response as an initial strategy for a clinical diagnosis of gastro-oesophageal reflux disease (GERD). Swedish multi-centre group in primary health care. Fam Pract 2000 17 : 401 404.
17. de Boer W, de Wit N, Geldof H, et al. Does Helicobacter pylori infection influence response rate or speed of symptom control in patients with gastroesophageal reflux disease treated with rabeprazole? Scand J Gastroenterol 2006 41 : 1147 1154.
18. Hatlebakk JG, Hyggen A, Madsen PH, et al. Heartburn treatment in primary care: randomised, double blind study for 8 weeks. BMJ 1999 319 : 550 553.
19. Diculescu M, Iacob R, Chira C, Mihaila D, Iacob S. Esomeprazole in the treatment of patients with heartburn and other upper gastrointestinal symptoms, referred to primary care - results of the in-practice evaluation program in Romania. Rom J Gastroenterol 2005 14 : 9 14.
20. Hansen AN, Bergheim R, Fagertun H, Lund H, Moum B. A randomised prospective study comparing the effectiveness of esomeprazole treatment strategies in clinical practice for 6 months in the management of patients with symptoms of gastroesophageal reflux disease. Int J Clin Pract 2005 59 : 665 671.
21. Meineche-Schmidt V, Hauschildt Juhl H, Ostergaard JE, Luckow A, Hvenegaard A. Costs and efficacy of three different esomeprazole treatment strategies for long-term management of gastro-oesophageal reflux symptoms in primary care. Aliment Pharmacol Ther 2004 19 : 907 915.
22. McColl E, Junghard O, Wiklund I, Revicki D. Assessing symptoms in gastroesophageal reflux disease: how well do clinicians' assessments agree with those of their patients? Am J Gastroenterol 2005 100 : 11 8.
23. McColl E. Best practice in symptom assessment: a review. Gut 2004 53 (Suppl 4 iv49 54.
24. Fallone CA, Guyatt GH, Armstrong D, et al. Do physicians correctly assess patient symptom severity in gastro-oesophageal reflux disease? Aliment Pharmacol Ther 2004 20 : 1161 1169.
25. Boeckxstaens GE, Smout A. Systematic review: role of acid, weakly acidic and weakly alkaline reflux in gastroesophageal reflux disease. Aliment Pharmacol Ther 2010 32 : 334 343.
26. Fass R, Shapiro M, Dekel R, Sewell J. Systematic review: proton-pump inhibitor failure in gastro-oesophageal reflux disease - where next? Aliment Pharmacol Ther 2005 22 : 79 94.
27. Reimer C, Sondergaard B, Hilsted L, Bytzer P. Proton-pump inhibitor therapy induces acid-related symptoms in healthy volunteers after withdrawal of therapy. Gastroenterology 2009 137 : 80 7. 7 e1.
28. Wiklund I, Carlsson R, Carlsson J, Glise H. Psychological factors as a predictor of treatment response in patients with heartburn: A pooled analysis of clinical trials. Scand J Gastroenterol 2006 41 : 288 293.
29. Rubenstein JH, Nojkov B, Korsnes S, et al. Oesophageal hypersensitivity is associated with features of psychiatric disorders and the irritable bowel syndrome. Aliment Pharmacol Ther 2007 26 : 443 452.
30. Wright CE, Ebrecht M, Mitchell R, Anggiansah A, Weinman J. The effect of psychological stress on symptom severity and perception in patients with gastro-oesophageal reflux. Psychosom Res 2005 59 : 415 424.
31. Naliboff BD, Mayer M, Fass R, et al. The effect of life stress on symptoms of heartburn. Psychosom Med 2004 66 : 426 434.
32. Guillemot F, Ducrotté P, Bueno L. Prevalence of functional gastrointestinal disorders in a population of subjects consulting for gastroesophageal reflux disease in general practice. Gastroenterol Clin Biol 2005 29 : 243 246.
33. Wiklund I, Butler-Wheelhouse P. Psychosocial factors and their role in symptomatic gastroesophageal reflux disease and functional dyspepsia. Scand J Gastroenterol Suppl 1996 220 : 94 100.
34. Rey E, García-Alonso M, Moreno-Ortega M, Almansa C, Alvarez-Sanchez A, Díaz-Rubio M. Influence of psychological distress on characteristics of symptoms in patients with GERD: the role of IBS comorbidity. Dig Dis Sci 2008 54 : 321 327.
35. El-Serag HB, Graham DY, Satia JA, Rabeneck L. Obesity is an independent risk factor for GERD symptoms and erosive esophagitis. Am J Gastroenterol 2005 100 : 1243 1250.
36. Hungin APS, Gunn SD, Bate CM, Turbitt ML, Wilcock C, Richardson PDI. A comparison of the efficacy of omeprazole 20 mg once daily with ranitidine 150 mg bd in the relief of symptomatic gastro-oesophageal reflux disease in general practice. British Journal of Clinical Research 1993 4 : 73 88.
37. Wiklund I, Carlsson J, Vakil N. Impact of gastroesophageal reflux symptoms on well-being in a random sample of the general population of a Swedish community: defining the transition from feeling well to feeling unwell. Can J Gastroenterol 2005 19 (Suppl C R0017.
38. Ronkainen J, Aro P, Storskrubb T, et al. Gastro-oesophageal reflux symptoms and health-related quality of life in the adult general population - the Kalixanda study. Aliment Pharmacol Ther 2006 23 : 1725 1733.
39. Arts J, Eisendrath P, Deviere J, Tack J. Empirical therapy for symptomatic gastroesophageal reflux disease in primary care: determinants of efficacy. Digestion 2007 76 : 207 214.
40. Crawley JA, Schmitt CM. How satisfied are chronic heartburn sufferers with their prescription medications? Results of the patient unmet needs survey. J Clin Outcomes Manage 2000 7 : 29 34.
41. Raghunath AS, Hungin AP, Mason J, Jackson W. Symptoms in patients on long-term proton pump inhibitors: prevalence and predictors. Aliment Pharmacol Ther 2009 29 : 431 439.
42. Hansen AN, Bergheim R, Fagertun H, Lund H, Wiklund I, Moum B. Long-term management of patients with symptoms of gastro-oesophageal reflux disease - a Norwegian randomised prospective study comparing the effects of esomeprazole and ranitidine treatment strategies on health-related quality of life in a general practitioners setting. Int J Clin Pract 2006 60 : 15 22.
43. Eggleston A, Katelaris PH, Nandurkar S, Thorpe P, Holtmann G. Clinical trial: The treatment of gastro-oesophageal reflux disease in primary care - prospective randomized comparison of rabeprazole 20 mg with esomeprazole 20 and 40 mg. Aliment Pharmacol Ther 2009 29 : 967 978.
44. Kaplan-Machlis B, Spiegler GE, Zodet MW, Revicki DA. Effectiveness and costs of omeprazole vs ranitidine for treatment of symptomatic gastroesophageal reflux disease in primary care clinics in West Virginia. Arch Fam Med 2000 9 : 624 630.
45. Talley NJ, Moore MG, Sprogis A, Katelaris P. Randomised controlled trial of pantoprazole versus ranitidine for the treatment of uninvestigated heartburn in primary care. Med J Aust 2002 177 : 423 427.
46. Venables TL, Newland RD, Patel AC, Hole J, Wilcock C, Turbitt ML. Omeprazole 10 milligrams once daily, omeprazole 20 milligrams once daily, or ranitidine 150 milligrams twice daily, evaluated as initial therapy for the relief of symptoms of gastro-oesophageal reflux disease in general practice. Scand J Gastroenterol 1997 32 : 965 973.